Is Retatrutide the Same as Mounjaro — or a Different Medicine?

Same goal, different architecture: how retatrutide and tirzepatide actually differ

The confusion is understandable. Retatrutide and tirzepatide both come from Eli Lilly's research programme, both target metabolic hormones involved in appetite and fat regulation, and both produced striking weight-loss results in early trials. But the molecules are not interchangeable.

Mounjaro's active ingredient, tirzepatide, is a dual agonist: it binds to GIP and GLP-1 receptors simultaneously. Retatrutide goes a step further, it is a triple agonist, also engaging glucagon receptors. That third pathway is thought to increase energy expenditure, not just reduce intake, which is why early-phase retatrutide data attracted so much attention. A phase 2 trial published in 2023 reported average weight reductions of around 17–24% over 48 weeks depending on dose, figures that exceeded anything seen with tirzepatide at the same stage of development.

So while the two drugs share a family resemblance (and the same manufacturer) they are pharmacologically distinct. Asking whether tirzepatide is the same as retatrutide is a bit like asking whether a bicycle is a tricycle. Related, yes. The same, no. If you are curious about what happens when the two compounds are considered together, our page on mixing retatrutide and tirzepatide explains what the science currently says about that question.

For a plain explanation of how Mounjaro works at the receptor level, the tirzepatide overview on this site runs through the mechanism in accessible terms. The NHS also covers the basics at nhs.uk/medicines/tirzepatide.

Where retatrutide actually stands right now, and what that means in the UK

As of summer 2026, retatrutide has no MHRA licence and is not available as a prescription medicine in the UK, or anywhere else. The phase 2 results were published; phase 3 trials are underway. That process typically takes years, and licensing approval in the UK would follow only after the MHRA reviews the full safety and efficacy data.

This matters practically. No regulated UK pharmacy can legally dispense retatrutide. If you encounter any seller claiming to supply it, that is a serious red flag, the product would not be a licensed medicine, and any substance sold under that name through unverified channels carries real risk. The MHRA has consistently warned about unlicensed and counterfeit weight-loss products circulating online.

People sometimes search for retatrutide after reading promising trial headlines, which is a reasonable response to genuinely exciting science. The question of whether it delivers on that promise at phase 3, and whether it receives a UK licence, remains open. What is available today, licensed and supported by robust trial evidence, is Mounjaro. SURMOUNT-1 showed average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, data that the NICE appraisal (TA1026) drew on when recommending tirzepatide for NHS use in December 2024.

You can check Mounjaro's current licensing status and the full evidence base via the Mounjaro information page here, or explore the broader range of weight-loss treatment options we cover.

The decision in front of you: wait for retatrutide or act on what's licensed now?

This is the real question most people are trying to answer when they search this topic. Retatrutide might, if licensed, become an option in the future. Mounjaro is an option today, clinically assessed, regulated, dispensed through pharmacies you can verify.

A quick habit worth building: before ordering any weight-loss medicine from an online pharmacy, spend thirty seconds checking the GPhC register at pharmacyregulation.org/registers. A legitimate pharmacy has a registration number that appears there. If it doesn't, walk away.

For most people the comparison isn't really retatrutide versus Mounjaro, it's whether Mounjaro (or Wegovy, the licensed semaglutide alternative) suits their situation now, or whether the NHS route is viable for them. Those are questions a prescriber works through with each patient individually. Eligibility depends on BMI, health history, and other factors that a standardised checklist can't capture on its own.

Context on what Mounjaro costs privately is on the Mounjaro prices page, which sets out what legitimate private pricing typically includes and what to watch for. The question of whether retatrutide and Mounjaro could theoretically be combined is a different matter entirely, the retatrutide and Mounjaro together page covers why that is not something with any evidence base or clinical guidance behind it.

A note on the terminology you'll see online

Search results mix up these medicines regularly. Some pages describe retatrutide as "the next Mounjaro" or "stronger Mounjaro", which collapses the distinction. Others conflate the compound names with brand names. A few things to hold onto:

Tirzepatide is the active ingredient; Mounjaro is the UK brand name for it. Retatrutide is a compound name, there is no UK brand name because there is no licence. The difference between tirzepatide and Mounjaro is purely one of naming, not pharmacology. The difference between retatrutide and Mounjaro is substantive: different molecule, different mechanism, different legal status.

If you are trying to understand which licensed option might suit you, that conversation belongs with a prescriber who can look at your full picture. Our clinical team (led by our clinical lead and staffed by GPhC-registered independent prescribers) reviews every consultation personally, on the day it arrives.